ATE168013T1 - Humanisierte chimäre anti-''icam-1'' antikörper, herstellungsverfahren und verwendung - Google Patents

Humanisierte chimäre anti-''icam-1'' antikörper, herstellungsverfahren und verwendung

Info

Publication number
ATE168013T1
ATE168013T1 AT91909612T AT91909612T ATE168013T1 AT E168013 T1 ATE168013 T1 AT E168013T1 AT 91909612 T AT91909612 T AT 91909612T AT 91909612 T AT91909612 T AT 91909612T AT E168013 T1 ATE168013 T1 AT E168013T1
Authority
AT
Austria
Prior art keywords
antibodies
icam
humanized
infection
production method
Prior art date
Application number
AT91909612T
Other languages
English (en)
Inventor
John Robert George Adair
Martyn Kim Robinson
Susan Margaret Bright
Robert A Rothlein
Original Assignee
Celltech Therapeutics Ltd
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech Therapeutics Ltd, Boehringer Ingelheim Pharma filed Critical Celltech Therapeutics Ltd
Application granted granted Critical
Publication of ATE168013T1 publication Critical patent/ATE168013T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT91909612T 1990-04-27 1991-04-29 Humanisierte chimäre anti-''icam-1'' antikörper, herstellungsverfahren und verwendung ATE168013T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909009548A GB9009548D0 (en) 1990-04-27 1990-04-27 Chimeric antibody and method

Publications (1)

Publication Number Publication Date
ATE168013T1 true ATE168013T1 (de) 1998-07-15

Family

ID=10675133

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91909612T ATE168013T1 (de) 1990-04-27 1991-04-29 Humanisierte chimäre anti-''icam-1'' antikörper, herstellungsverfahren und verwendung

Country Status (14)

Country Link
EP (1) EP0528931B1 (de)
JP (1) JPH05507406A (de)
AT (1) ATE168013T1 (de)
AU (1) AU649682B2 (de)
BR (1) BR9106394A (de)
CA (1) CA2081479A1 (de)
DE (1) DE69129743T2 (de)
DK (1) DK0528931T3 (de)
ES (1) ES2118084T3 (de)
FI (1) FI924819A (de)
GB (1) GB9009548D0 (de)
HU (1) HUT66103A (de)
NO (2) NO924088L (de)
WO (1) WO1991016928A1 (de)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA896668B (en) * 1988-09-01 1990-06-27 Molecular Therapeutics Inc A human rhinovirus receptor protein that inhibits virus infectivity
EP0459577A3 (en) * 1990-06-01 1992-08-05 Merck & Co. Inc. Microbially expressed portions of a monoclonal antibody block rhinovirus attachment to cell receptors
US5686582A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
US5674982A (en) * 1990-07-20 1997-10-07 Bayer Corporation Multimeric form of human rhinovirus receptor protein
US5223396A (en) * 1991-05-03 1993-06-29 Boehringer Ingelheim Pharmaceuticals, Inc. Method for detecting organ transplant rejection
US5629162A (en) * 1991-06-11 1997-05-13 The Center For Blood Research Method of identifying agents which modulate ICAM-3 binding to LFA-1
WO1993006864A1 (en) * 1991-10-01 1993-04-15 The General Hospital Corporation Preventing allograft rejection with antibodies to adhesion molecules
US6818743B1 (en) 1992-01-27 2004-11-16 Icos Corporation I-CAM related protein
CA2107097A1 (en) * 1992-01-27 1993-07-28 Michael W. Gallatin Icam-related protein
US5702917A (en) * 1992-01-27 1997-12-30 Icos Corporation Polynucleotides encoding human ICAM-4
US5532127A (en) * 1992-01-27 1996-07-02 Icos Corporation Assay for 1-CAM related protein expression
US5773293A (en) * 1992-01-27 1998-06-30 Icos Corporation Anti-ICAM-4 antibodies and hybridomas
US5525487A (en) * 1992-01-27 1996-06-11 Icos Corporation DNA encoding I-CAM related protein
US6153395A (en) * 1992-01-27 2000-11-28 Icos Corporation ICAM-related protein
US5700658A (en) * 1992-01-27 1997-12-23 Icos Corporation ICAM-4 materials and methods
US5753502A (en) * 1993-08-05 1998-05-19 Icos Corporation Neuron-specific ICAM-4 promoter
US6100383A (en) * 1992-01-27 2000-08-08 Icos Corporation Fusion proteins comprising ICAM-R polypeptides and immunoglobulin constant regions
US5989843A (en) * 1992-01-27 1999-11-23 Icos Corporation Methods for identifying modulators of protein kinase C phosphorylation of ICAM-related protein
US5852170A (en) * 1992-01-27 1998-12-22 Icos Corporation ICAM-4 materials and methods
US5837822A (en) * 1992-01-27 1998-11-17 Icos Corporation Humanized antibodies specific for ICAM related protein
US5869262A (en) * 1992-01-27 1999-02-09 Icos Corporation Method for monitoring an inflammatory disease state by detecting circulating ICAM-R
ATE185815T1 (de) * 1992-02-28 1999-11-15 Univ Texas Verwendung einer therapeutischen zusammensetzungen zur behandlung von verbrennungen
ZA936128B (en) * 1992-08-21 1995-02-20 Genentech Inc Method for treating a LFA-1 mediated disorder
US5472693A (en) * 1993-02-16 1995-12-05 The Dow Chemical Company Family of anti-carcinoembryonic antigen chimeric antibodies
US6884590B1 (en) 1994-02-11 2005-04-26 Cedars-Sinai Medical Center Methods of screening for ulcerative colitis and crohn's disease
US5681699A (en) * 1994-02-11 1997-10-28 Cedars-Sinai Medical Center Methods of diagnosing ulcerative colitis and Crohn's disease
WO1997000956A1 (en) * 1995-06-20 1997-01-09 Trustees Of Boston University Hypoxia-responsive adhesion molecules, specific antibodies, and their uses
US5914112A (en) * 1996-01-23 1999-06-22 Genentech, Inc. Anti-CD18 antibodies in stroke
US20020081294A1 (en) 1996-01-23 2002-06-27 Genentech, Inc. Co-administration of a thrombolytic and an anti-CD18 antibody in stroke
KR100847441B1 (ko) 1996-09-26 2008-07-21 츄가이 세이야꾸 가부시키가이샤 인간의 부갑상선 호르몬 관련 펩티드에 대한 항체
UA74130C2 (uk) 1997-05-15 2005-11-15 Чугаі Сейяку Кабусікі Кайся ЗАСТОСУВАННЯ АНТИТІЛА ПРОТИ БІЛКА, СПОРІДНЕНОГО З ПАРАТИРЕОЇДНИМ ГОРМОНОМ (PTHrP), АБО ЙОГО ФУНКЦІОНАЛЬНО АКТИВНОГО ФРАГМЕНТА І/АБО ЙОГО МОДИФІКОВАНОГО ФРАГМЕНТА ДЛЯ ВИРОБНИЦТВА ЛІКАРСЬКОГО ЗАСОБУ ДЛЯ ПРОФІЛАКТИКИ АБО ЛІКУВАННЯ КАХЕКСІЇ
CN1068524C (zh) * 1997-06-23 2001-07-18 叶庆炜 一种治疗顽症牛皮癣的药物
US7531643B2 (en) 1997-09-11 2009-05-12 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody inducing apoptosis
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
BR9909382A (pt) 1998-04-03 2000-12-05 Chugai Pharmaceutical Co Ltd Anticorpo humanizado contra o fator tissular humano (tf) e processo de produção de anticorpo humanizado
ATE310536T1 (de) * 1998-08-04 2005-12-15 Univ Pennsylvania Zielrichtung und verlängerte assoziation von wirkstoffen an die luminale oberfläche der pulmonaren vaskularen endothelzellen
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
US6670321B1 (en) 1998-12-30 2003-12-30 The Children's Medical Center Corporation Prevention and treatment for retinal ischemia and edema
US7696325B2 (en) 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis
ATE439145T1 (de) 1999-03-19 2009-08-15 Genentech Inc Behandlung von lfa-1 assozieerten krankheiten durch gesteigerte dosen von lfa-1 antagonist
US6582698B1 (en) 1999-03-19 2003-06-24 Genentech, Inc. Treatment method
JP4880153B2 (ja) * 1999-06-24 2012-02-22 ザ ジョンズ ホプキンス ユニヴァーシティ Ｈｉｖの経上皮伝染を予防する組成物および方法
TWI255718B (en) 1999-07-02 2006-06-01 Chugai Pharmaceutical Co Ltd Ameliorative agent for low vasopressin concentration
US7674466B2 (en) 1999-08-05 2010-03-09 The Trustees Of The University Of Pennsylvania Targeting and prolonging association of drugs to the luminal surface of the pulmonary vascular endothelial cells using antibodies that bind to ICAM-1
US20030158382A1 (en) 2000-04-21 2003-08-21 Nobutaka Wakamiya Novel collectins
DE60137417D1 (de) 2000-04-28 2009-03-05 Chugai Pharmaceutical Co Ltd Zellproliferation-inhibitoren
JPWO2002033072A1 (ja) 2000-10-20 2004-02-26 中外製薬株式会社 低分子化ｔｐｏアゴニスト抗体
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US20030096299A1 (en) * 2001-07-09 2003-05-22 Valerie Wittamer Natural ligand of G protein coupled receptor ChemR23 and uses thereof
US20030138440A1 (en) 2001-07-19 2003-07-24 Fang Fang Multimeric proteins and methods of making and using same
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
JP2004279086A (ja) 2003-03-13 2004-10-07 Konica Minolta Holdings Inc 放射線画像変換パネル及び放射線画像変換パネルの製造方法
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP1648998B1 (de) 2003-07-18 2014-10-01 Amgen Inc. Agentien mit spezifischer bindung an hepatozyten-wachstumsfaktor
EP2070947B1 (de) * 2003-12-05 2014-06-11 multimmune GmbH Anti-Hsp70-Antikörper zur Therapie und Diagnose
WO2005123777A2 (en) 2004-06-09 2005-12-29 Genentech, Inc. Method of treating granuloma annulare or sarcoid
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
JP5057967B2 (ja) 2005-03-31 2012-10-24 中外製薬株式会社 ｓｃ（Ｆｖ）２構造異性体
KR101360671B1 (ko) 2005-06-10 2014-02-07 추가이 세이야쿠 가부시키가이샤 ｓｃ（Ｆｖ）２를 함유하는 의약조성물
CN101237890A (zh) 2005-06-10 2008-08-06 中外制药株式会社 含有葡甲胺的蛋白质制剂的稳定剂及其利用
WO2007025166A2 (en) 2005-08-25 2007-03-01 Repair Technologies, Inc. Devices, compositions and methods for the protection and repair of cells and tissues
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8221751B2 (en) 2006-06-21 2012-07-17 Oncotherapy Science, Inc. Tumor-targeting monoclonal antibodies to FZD10 and uses thereof
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
JP5889529B2 (ja) 2007-07-27 2016-03-22 ヤンセン・サイエンシズ・アイルランド・ユーシー アミロイド原性疾患の処置
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US8026343B2 (en) * 2008-08-08 2011-09-27 Dinona Inc. Antibody modulating the differentiation and function of dendritic cells via binding intercellular adhesion molecule-1 and use thereof
CA2741798A1 (en) 2008-10-28 2010-05-06 Shionogi & Co., Ltd. Anti-muc1 antibody
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
WO2010075579A2 (en) 2008-12-24 2010-07-01 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (mr-uc) requiring colectomy
US20130004490A1 (en) 2009-12-14 2013-01-03 The United States of America, as represented by the Secretary, Department Delivery of transthyretin across the blood-brain barrier as a treatment for alzheimer's disease
ES2701626T3 (es) 2009-12-28 2019-02-25 Oncotherapy Science Inc Anticuerpos anti-CDH3 y sus usos
KR101434029B1 (ko) * 2012-09-14 2014-08-26 서울대학교산학협력단 Ｉｃａｍ－1에 대한 항체 및 그 용도
WO2014160883A1 (en) 2013-03-27 2014-10-02 Cedars-Sinai Medical Center Treating fibrosis and inflammation by inhibiting tl1a
WO2015010108A1 (en) 2013-07-19 2015-01-22 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
US9795624B2 (en) 2015-05-04 2017-10-24 Research Foundation Of The City University Of New York Cationic polymers as co-drugs for chemotherapeutic agents
JP7082945B2 (ja) 2016-03-17 2022-06-09 シーダーズ―シナイ メディカル センター Ｒｎａｓｅｔ２により炎症性腸疾患を診断する方法
US11260132B2 (en) 2017-03-16 2022-03-01 Children's Medical Center Corporation Engineered liposomes as cancer-targeted therapeutics

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ES2080044T3 (es) * 1987-05-04 1996-02-01 Dana Farber Cancer Inst Inc Moleculas de adhesion intercelular y sus ligandos de fijacion.
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
ZA903223B (en) * 1989-04-28 1991-02-27 Baylor College Medicine Dissemination of hiv-1 infected cells
GB9009549D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Recombinant antibody and method

Also Published As

Publication number Publication date
EP0528931A4 (en) 1993-04-28
GB9009548D0 (en) 1990-06-20
NO984136L (no) 1992-12-23
NO924088L (no) 1992-12-23
DE69129743D1 (de) 1998-08-13
AU649682B2 (en) 1994-06-02
EP0528931B1 (de) 1998-07-08
JPH05507406A (ja) 1993-10-28
EP0528931A1 (de) 1993-03-03
ES2118084T3 (es) 1998-09-16
WO1991016928A1 (en) 1991-11-14
AU7860391A (en) 1991-11-27
HU9203370D0 (en) 1993-01-28
FI924819A0 (fi) 1992-10-23
HUT66103A (en) 1994-09-28
FI924819A (fi) 1992-10-23
DK0528931T3 (da) 1999-04-19
NO924088D0 (no) 1992-10-22
BR9106394A (pt) 1993-04-27
NO984136D0 (no) 1998-09-08
CA2081479A1 (en) 1991-10-28
DE69129743T2 (de) 1999-02-11

Similar Documents

Publication Publication Date Title
ATE168013T1 (de) Humanisierte chimäre anti-''icam-1'' antikörper, herstellungsverfahren und verwendung
ATE354655T1 (de) Humane antikörper gegen ctla-4 und deren verwendungen
EP1245676A4 (de) Humane monoklonale antikörper gegen den tgf-beta ii rezeptor und dessen medizinische verwendung
PL359854A1 (en) Antibodies to human mcp-1
ATE403680T1 (de) Herstellung tetravalenter antikörper
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
DK1265928T3 (da) RSV-neutraliserende antistoffer med ultra høj affinitet
DK69890A (da) Monoklonale antistoffer, der er reaktive med cachetin
DE3751908T2 (de) Chimärisches Murine-Mensch-Immunoglobulin, spezifisch für tumorassoziertes 17-1A Antigen
DE3686313D1 (de) Anti-immuntoxine gegen menschlichen eierstockkrebs und verfahren zu deren verwendung.
MD1374G2 (ro) Anticorpi monoclonali imunostimulatori, procedeu de obţinere a acestora, linii celulare, metodă de tratare a maladiilor şi compoziţie farmaceutică
CA2093928A1 (en) Monoclonal antibodies for detection and treatment of cancer
TR200102493T2 (tr) IgE'nin C-epsilon-3 veya C-epsilon-4 alanlarından türetilmiş epitoplar veya mimotoplar.
DE69125485D1 (de) Verfahren und zwischenprodukte synthetischer antikörperderivate
ES2009140A6 (es) Un metodo de produccion de anticuerpos monoclonales humanos de proteccion cruzada y de composiciones que los contienen.
ATE248189T1 (de) Antikörper gegen vasp (vasodilator-stimulated phosphoprotein), hybridomzellen für deren gewinnung, und deren verwendung
YU22693A (sh) Rekombinantna humana monoklonalna antitela koja neutrališu hiv, za sprečavanje i tretiranje hiv infekcije
DE3775182D1 (de) Monoklonale antikoerper gegen menschliche ige-rezeptoren auf lymphocyten, diese antikoerper produzierende hybridomas und reaktionsansaetze zum gebrauch dieser antikoerper.
FI971879A0 (fi) Allogeenisten ja ksenogeenisten proteiinien vasta-aineet, niiden käyttö diagnoosissa ja hoidossa ja menetelmät niiden määrittämiseksi
ATE372349T1 (de) Verwendung von basiliximab zur behandlung von rheumatoider arthritis und hauterkrankungen
ATE207119T1 (de) Die herstellung von menschlichen, monoklonalen antikörpern, die gegen das oberflächenantigen von hepatitis b aktiv sind
RU92016335A (ru) Химерное антитело, днк, вектор, клетка, способ получения химерного антитела, способы лечения, способ появления роста клеток опухоли, способ подавления инфицирования лейкоцитов, способ подавления внесосудистой миграции инфицированных лейкоцитов, фармацевтическая композиция, способы диагностики
ATE94759T1 (de) Verwendung von dextransulfat, gegebenenfalls in kombination mit anti-androgenen mitteln zur behandlung des humanen protatakarzinoms.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee